Investigative pathology: leading the post-genomic revolution
暂无分享,去创建一个
Massimo Loda | M. Loda | C. Fletcher | M. Bosenberg | D. Berman | B. Thurberg | Marcus W Bosenberg | David M Berman | Robin L Orwant | Beth L Thurberg | Gulio F Draetta | Christopher DM Fletcher | G. Draetta
[1] P. Jänne. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. , 2008, Lung cancer.
[2] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] E. Mardis. The $1,000 genome, the $100,000 analysis? , 2010, Genome Medicine.
[4] R. Drapkin,et al. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Aparicio,et al. Does massively parallel DNA resequencing signify the end of histopathology as we know it? , 2010, The Journal of pathology.
[6] Ryan D. Morin,et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. , 2009, The New England journal of medicine.
[7] Robert B. Hartlage,et al. This PDF file includes: Materials and Methods , 2009 .
[8] A. Ashworth,et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas , 2010, The Journal of pathology.
[9] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[10] Andrew Menzies,et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.
[11] Lee T. Sam,et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. , 2011, Genome research.
[12] Ryan D. Morin,et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.
[13] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[14] Emily H Turner,et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome , 2010, Nature Genetics.
[15] P. Stankiewicz,et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. , 2010, The New England journal of medicine.
[16] P. Shannon,et al. Analysis of Genetic Inheritance in a Family Quartet by Whole-Genome Sequencing , 2010, Science.
[17] R. Drapkin,et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis , 2007, Current opinion in obstetrics & gynecology.
[18] P. Meltzer,et al. High frequency of BRAF mutations in nevi , 2003, Nature Genetics.
[19] M. Meyerson,et al. A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening , 2006, Clinical Cancer Research.
[20] A. Ashworth,et al. Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.
[21] Richard A. Moore,et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.
[22] D. Hayes,et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.